Efficacy of Ceftibuten for Acute Otitis Media Caused by Hemophilus Influenzae: an Animal Study

Abstract

Ceftibuten is a new oral cephalosporin with an unusual stability to β-lactamases that can hydrolyze other extended-spectrum cephalosporins. Using the chinchilla animal model, we compared the efficacy of ceftibuten (n = 33) with that of saline (n = 34), ampicillin (n = 32), and cefixime (n = 31) for the treatment of acute otitis media caused by β-lactamase—producing nontypeable Hemophilus influenzae. Ceftibuten was superior to ampicillin regarding the time necessary to sterilize the middle ear (p < .001) and eliminate effusion (p < .001). The mean days of therapy required for bacteriologic cure were 2.57 for ceftibuten, 2.95 for cefixime, 7.95 for ampicillin, and 8.16 for saline. At the conclusion of therapy, chinchillas treated with ceftibuten had a significantly lower prevalence of positive cultures and middle ear effusion than did animals treated with ampicillin. No significant differences were observed between ceftibuten and cefixime. The results of this randomized, investigator-blinded experiment warrant further consideration of ceftibuten as a second-line agent for acute otitis media caused by ampicillin-resistant H influenzae.

Keywords

acute otitis media ceftibuten cephalosporins drug therapy

Get full access to this article

View all access options for this article.

References

Vital and health statistics: current estimates from the national health interview survey, 1989. Series 10, No. 176. Publication 90–1504. Hyattsville, Md: US Department of Health and Human Services, 1990: 20.

Bluestone

Lundgren

Tos

Takahara

. Frequency of bacteria isolated from middle ear effusions of children from the United States, Finland, Japan, and Denmark. Ann Otol Rhinol Laryngol 1990; 99(suppl 149): 42–3.

McCracken

. Selection of antimicrobial agents for treatment of acute otitis media with effusion. Pediatr Infect Dis J 1987; 6: 985–8.

Hotaling

Doyle

Cantekin

. Efficacy of a new cephalosporin for acute otitis media. Arch Otolaryngol Head Neck Surg 1987; 113: 370–3.

Howie

Owen

. Bacteriologic and clinical efficacy of cefixime compared with amoxicillin in acute otitis media. Pediatr Infect Dis J 1987; 6: 989–91.

Bauerinfeind

. Ceftibuten: Bacteriocidal kinetics and comparative in-vitro activity against Enterobacteriaceae producing extended broad-spectrum β-lactamase. Diagn Microbiol Infect Dis 1991; 14: 89–92.

Schering-Plough research. Investigator's brochure: information for the investigational new drug ceftibuten (SCH 39720). Kenilworth, NJ: Schering Corp, 1990: 51.

Doyle

Supance

Marshak

Cantekin

Bluestone

Rohn

. An animal model of acute otitis media consequent to β-lactamase—producing nontypable Haemophilus influenzae. Otolaryngol Head Neck Surg 1982; 90: 831–6.

Dixon

, ed. BMDP statistical software manual. 1990 Revision. Berkeley, Calif: University of California Press, 1990: 253–65, 739–58.

10.

Nelson

. 1991–1992 Pocketbook of pediatric antimicrobial therapy. 9th ed. Baltimore, Md: Williams & Wilkins, 1991: 2–3.

11.

Keleti

Bluestone

. In vitro study of a new oral cephalosporin: CL 284,635 (cefixime). Ann Otol Rhinol Laryngol 1988; 97(suppl 133): 21–2.

12.

Rosenfeld

Doyle

Swarts

Seroky

Pinero

Perez B

. Third-generation cephalosporins in the treatment of acute pneumococcal otitis media. An animal study. Arch Otolaryngol Head Neck Surg 1992; 118: 49–52.

13.

Giebink

Payne

Mills

. Experimental otitis media due to Streptococcus pneumoniae: Immunopathogenic response in the chinchilla. J Infect Dis 1976; 134: 595–604.